Search
Icotrokinra
go.drugbank.com/drugs/DB21724ApprovedInvestigational[L56108,L56118] Icotrokinra was approved by the US FDA in March 2026 for the systemic treatment of moderate-to-severe plaque psoriasis.[L56108] … Icotrokinra is a first-in-class, targeted oral peptide and interleukin-23 (IL-23) receptor antagonist.
FT516
go.drugbank.com/drugs/DB15732InvestigationalFT516 is an investigational and engineered off-the-shelf natural killer (NK) cell therapy originating from induced pluripotent stem cells (iPSC). … FT516 is currently being tested against acute myeloid leukemia, B-cell lymphoma, and solid tumors in combination with other compounds. It is also a potential therapy for COVID-19.
Fexinidazole
go.drugbank.com/drugs/DB12265Approved[A237555, L35940] It is currently marketed by Sanofi-Aventis.[L35940] … Human African trypanosomiasis (HAT, also colloquially referred to as sleeping sickness), caused by _T. brucei gambiense_ and _T. brucei rhodesiense_, remains a moderate risk (>1/10,000 inhabitants per
Dimethyltryptamine
go.drugbank.com/drugs/DB01488IllicitInvestigationalIt apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.
Salmeterol
go.drugbank.com/drugs/DB00938ApprovedInvestigationalSalmeterol is a long-acting beta-2 adrenergic receptor agonist drug that is currently prescribed for the treatment of asthma and chronic obstructive pulmonary disease COPD. … [A190477] Salmeterol's structure is similar to salbutamol's with an aralkyloxy-alkyl substitution on the amine.[A183737] Salmeterol was granted FDA approval on 4 February 1994.[L11542]
Mixtures: HOVID CLEFAN-S POWDER FOR INHALATION 50/250MCGProducts: Serevent- Aem 25mcg/aemDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.
Sugemalimab
go.drugbank.com/drugs/DB16641ApprovedInvestigational[L32868, L32873, L53333] The antibody is produced in Chinese hamster ovary cells by recombinant DNA technology. … Sugemalimab is a fully human, full-length anti-programmed death-ligand 1 (PD-L1) monoclonal antibody (of the IgG4 isotype) discovered by CStone Pharmaceuticals.
Sulodexide
go.drugbank.com/drugs/DB06271ApprovedInvestigationalWithdrawnSulodexide is a mixture of glycosaminoglycans (GAGs) composed of dermatan sulfate (DS) and fast moving heparin (FMH).
Tegafur-uracil
go.drugbank.com/drugs/DB09327ApprovedIt was developed as an anti-cancer therapy by Taiho Pharmaceutical Co Ltd.[A32073] It is approved in different countries but it is not yet approved by the FDA, Health Canada or EMA. … Tegafur-uracil is an anti-tumor compound containing tegafur (1-(2-tetrahydrofuryl)-5-fluorouracil) and uracil in a molar ratio of 1:4.
Carboplatin
go.drugbank.com/drugs/DB00958ApprovedInvestigationalCarboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma.[L32253] Early clinical studies of carboplatin were performed in 1982. … [A230523] Carboplatin was developed as an analog of [cisplatin] with reduced nephrotoxicity and vomiting.[A230463,A230523] Carboplatin was granted FDA approval on 3 March 1989.[L32248]
Products: CARBOPLATIN DEM 150 MG/15 ML IV İNFÜZYON ÇÖZELTİSİ İÇEREN FLAKON, 1 ADET, CARBOPLATIN DEM 450 MG/45 ML IV İNFÜZYON ÇÖZELTİSİ İÇEREN FLAKON, 1 ADET